Dr. Tashkin is a Diplomate in Internal Medicine of the American Board of Pulmonary Diseases and is considered a leading expert on the pulmonary consequences of smoking marijuana and crack cocaine.
LONG BEACH, CA, December 09, 2019 /24-7PressRelease/ -- Marquis Who's Who, the world's premier publisher of biographical profiles, is proud to present Donald P. Tashkin, MD, with the Albert Nelson Marquis Lifetime Achievement Award. An accomplished listee, Dr. Tashkin celebrates many years' experience in his professional network, and has been noted for achievements, leadership qualities, and the credentials and successes he has accrued in his field. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.
Influenced by the dedication of a family physician when he was a child, Dr. Tashkin, a medical educator, has served the University of California Los Angeles for 50 years. Hired by UC Los Angeles' School of Medicine as an Assistant Professor of Medicine in the Division of Pulmonary Medicine in 1969, he subsequently became a Distinguished Professor of Medicine within the Division of Pulmonary and Critical Care Medicine, after which he attained the title of Distinguished Emeritus Professor in 2012. Though an Emeritus Professor, Dr. Tashkin has continued to serve the University as an educator, mentor of fellows and junior faculty and nationally funded clinical researcher. Likewise, he was a longtime director of the Pulmonary Function Laboratory at the UC Los Angeles Medical Center from 1971 to 2004.
Alongside his academic appointments, Dr. Tashkin is a past attending physician at the UCLA Medical Center, the Wadsworth Veterans Affairs Hospital and the Sepulveda Veterans Affairs Hospital, beginning in 1971. During his career, he has also served as a consultant to several entities, including the National Institute on Drug Abuse/National Institutes of Health, the Rand Corporation, the American Academies of Science, Engineering and Medicine, the World Health Organization and the American Lung Association, among others. Notably, Dr. Tashkin was also affiliated with the National Institute on Drug Abuse for organizing a national conference on the cardiopulmonary effects of crack cocaine.
To prepare for his career, Dr. Tashkin pursued a formal education at the University of Pennsylvania, where he earned a Bachelor of Arts in chemistry in 1957 and Doctor of Medicine in 1961. From 1961 to 1962, he worked as a rotating intern at the Albert Einstein Medical Center, and 'from 1962 to 1965, he undertook a residency in internal medicine at the Philadelphia Veterans Affairs Hospital. Dr. Tashkin next served as a Lieutenant Commander and an assistant chief of pulmonary medicine at the U.S. Public Health Service Hospital in Staten Island, NY from 1965 to 1967, and a Public Health Service academic fellow in chest disease and pulmonary physiology at the UC Los Angeles School of Medicine from 1967 to 1969.
Dr. Tashkin is a Diplomate in Internal Medicine of the American Board of Pulmonary Diseases and is considered a leading expert on the pulmonary consequences of smoking marijuana and crack cocaine. He has also conducted research on the effects of air pollution on the lungs, the pathophysiology, prevention and treatment of chronic obstructive pulmonary disease and the pharmacotherapy of asthma. Dr. Tashkin has contributed over 570 peer-reviewed articles to professional publications, as well as numerous review papers and book chapters throughout his career and has been a guest editor for numerous scientific journals, such as the New England Journal of Medicine, the American Journal of Pulmonary and Critical Care Medicine, CHEST, Lancet, Lancet Pulmonary Medicine, the European Respiratory Journal, the Journal of Asthma and Clinical Immunology, the Journal of Pharmacology and Experimental Therapeutics, the Annals of Rheumatic Diseases and Arthritis and Rheumatology among many others.
To remain aware of developments in the field of Medicine, Dr. Tashkin has further maintained his affiliation with several organizations. He is a past president, president-elect, secretary and program chairman of the Trudeau Society of Los Angeles and the chest disease section of the Los Angeles Medical Association, as well as a member of the American Federation for Clinical Research, the Western Society for Clinical Investigation, the International Cannabis Research Society, the American College of Chest Physicians and the American Thoracic Society. Likewise, Dr. Tashkin is a fellow of the American College of Physicians, the American College of Chest Physicians and the American Thoracic Society.
As a testament to his success in his chosen field of Pulmonary Medicine, Dr. Tashkin has been recognized with accolades from the American Lung Association, the Scleroderma Foundation, the Trudeau Society of Los Angeles and the American Thoracic Society. In addition, he was featured in numerous editions of Who's Who in America between 1995 and 2016. However, he cites the highlight of his career as his time working with Dr. Sydney Cohen of the University of California Los Angeles in the 1960s and 1970s. Studying the behavioral and physiological effects of marijuana on the human body, both he and Dr. Cohen found that smoking marijuana dilated lung airways instead of constricting airways, as previously assumed. Publishing these results in the New England Journal of Medicine, Dr. Tashkin then applied for his own grants in marijuana research and he was subsequently continuously funded for over three decades in this area of investigation. He was also Principal Investigator at UCLA of the landmark Lung Health Study, which evaluated the impact of early intervention in chronic obstructive pulmonary disease (COPO), and more recently, the NIH-supported SubPopulations and Intermediate Outcome Measures in COPO Study (SPIROMICS), an ongoing observational study for identifying biomarkers to serve as surrogate endpoints for studies of patients with COPO that might facilitate future clinical trials of the efficacy of novel drugs for this heterogeneous disease.
About Marquis Who's Who®
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Today, Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis® now publishes many Who's Who titles, including Who's Who in America®, Who's Who in the World®, Who's Who in American Law®, Who's Who in Medicine and Healthcare®, Who's Who in Science and Engineering®, and Who's Who in Asia®. Marquis® publications may be visited at the official Marquis Who's Who® website at www.marquiswhoswho.com.
# # #